Beone Medicines (06160.HK) has delivered a standout financial report, reinforcing the strong momentum in the innovative drug sector. Following the impressive results from CXO leader WuXi AppTec, the biotech giant announced on the evening of August 5th that its net profit attributable to parent company shareholders for the first half of 2026 reached 3.271 billion yuan, a staggering 627.1% increase year-over-year. The company has also raised its full-year 2026 revenue forecast to a range of 44.9 billion to 46.2 billion yuan.
This performance signals that Beone Medicines is transitioning from a high-investment phase into a period of commercial realization. On August 6th, shares of Beone Medicines on the Hong Kong Stock Exchange initially dipped nearly 3% in early trading before staging a sharp reversal to trade in the green, gaining 1%. The broader Hong Kong Stock Connect Innovative Drug Index also recovered in tandem. The Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF (520880), which is fully invested in innovative drug research and development companies, has been trading at a premium on the exchange, indicating active buying pressure.
Where to focus your strategy
According to the latest weekly report from Guojin Securities, innovative drug companies are approaching a turning point for profitability. With a dense calendar of clinical data readouts expected throughout the year and positive progress in overseas clinical trials for out-licensed pipeline assets, the brokerage is bullish on the sector's investment opportunities. Specific strategies include: 1) Focusing on the earnings reporting season to identify companies with results that exceed expectations; 2) Monitoring key medical conference events to capture the release of pivotal clinical data; and 3) Concentrating on core therapeutic areas, including small nucleic acids, bispecific antibodies, and ADCs, to capitalize on the dividend phase of industrial maturation.
Investment tools for tracking the innovative drug theme
Investors looking to participate in the innovative drug rally can consider two main vehicles: The Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF (520880) is a 100% pure-play on innovative drug R&D companies, with its top ten holdings accounting for over 70% of the portfolio. This ETF offers high beta and a T+0 trading mechanism, as it is based on Hong Kong-listed underlying assets. The Huabao Pharmaceutical ETF (562050) is the only ETF in the market tracking the Pharmaceutical Index, featuring a unique allocation of 72% innovative drugs and 22% traditional Chinese medicine. This combination provides exposure to both the high-growth potential of innovative drugs and the high-dividend yield characteristics of traditional Chinese medicine stocks.
Data sourced from the Shanghai, Shenzhen, and Hong Kong Stock Exchanges, the CSI Index Company, the Hang Seng Index Company, and PharmaCube. Institutional views are based on a report from Guotai Junan Securities dated July 15, 2026, titled "9 Innovative Drugs to Read Out Global Phase III Data in 2026; Innovative Drugs Approaching Global Sales Realization."
Risk disclosures
Note: The index constituent stocks mentioned are for illustrative purposes only and do not constitute investment advice, nor do they represent the holdings or trading activities of any fund managed by the manager. The annual historical returns/volatility for the CSI Pharmaceutical Index from 2021 to 2025 are: -9.10%/23.43%, -21.09%/25.92%, -3.70%/18.25%, -6.53%/29.46%, and 9.38%/16.12%. For the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, the figures are: -22.72%/35.30%, -16.48%/44.08%, -19.76%/34.79%, -14.16%/38.47%, and 66.32%/39.20%. The composition of index constituents is adjusted periodically according to the index compilation rules. Past performance does not guarantee future results. Fund managers have assessed the risk level of the medical ETF and the Huabao Pharmaceutical ETF and their feeder funds as R3-Medium Risk, suitable for investors with a balanced (C3) risk profile or above. The Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF and its feeder fund, as well as the Huabao Hong Kong Stock Connect Medical ETF, are assessed as R4-Medium-High Risk, suitable for investors with an aggressive (C4) risk profile or above. Any information in this article is for reference only. Investors are solely responsible for their own investment decisions. The views, analysis, and forecasts herein do not constitute investment advice and shall not be held liable for any direct or indirect losses arising from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of any specific fund. Past performance is not indicative of future results. Investing in funds involves risk.
Comments